These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 31198224)

  • 1. Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial.
    Satirapoj B; Korkiatpitak P; Supasyndh O
    Clin Kidney J; 2019 Jun; 12(3):326-332. PubMed ID: 31198224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.
    Otoda T; Sekine A; Uemoto R; Tsuji S; Hara T; Tamaki M; Yuasa T; Tamaki T; Matsuhisa M; Aihara KI
    Diabetes Ther; 2024 Jan; 15(1):127-143. PubMed ID: 37883001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
    Sugiyama S; Jinnouchi H; Yoshida A; Hieshima K; Kurinami N; Jinnouchi K; Tanaka M; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2019 Apr; 11(4):267-274. PubMed ID: 30937117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of exenatide twice daily and dapagliflozin, alone and in combination, on markers of kidney function in obese patients with type 2 diabetes: A prespecified secondary analysis of a randomized controlled clinical trial.
    van Ruiten CC; van der Aart-van der Beek AB; IJzerman RG; Nieuwdorp M; Hoogenberg K; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2021 Aug; 23(8):1851-1858. PubMed ID: 33908691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of sodium-glucose cotransporter 2 inhibitor, tofogliflozin, on the indices of renal tubular function in patients with type 2 diabetes.
    Nunoi K; Sato Y; Kaku K; Yoshida A; Suganami H
    Endocrinol Diabetes Metab; 2018 Apr; 1(2):e00015. PubMed ID: 30815551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
    Sugiyama S; Jinnouchi H; Kurinami N; Hieshima K; Yoshida A; Jinnouchi K; Tanaka M; Nishimura H; Suzuki T; Miyamoto F; Kajiwara K; Jinnouchi T
    J Clin Med Res; 2018 Jun; 10(6):466-477. PubMed ID: 29707088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of action of the sodium-glucose cotransporter-2 (SGLT2) inhibitor canagliflozin on tubular inflammation and damage: A post hoc mediation analysis of the CANVAS trial.
    Sen T; Koshino A; Neal B; Bijlsma MJ; Arnott C; Li J; Hansen MK; Ix JH; Heerspink HJL
    Diabetes Obes Metab; 2022 Oct; 24(10):1950-1956. PubMed ID: 35635326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the sodium-glucose cotransporter type-2 inhibitor dapagliflozin on glomerular filtration rate in healthy cats.
    Gal A; Burton SE; Weidgraaf K; Singh P; Lopez-Villalobos N; Jacob A; Malabu U; Burchell R
    Domest Anim Endocrinol; 2020 Jan; 70():106376. PubMed ID: 31585313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of dapagliflozin on serum uric acid levels in hospitalized type 2 diabetic patients with inadequate glycemic control: a randomized controlled trial.
    Hao Z; Huang X; Shao H; Tian F
    Ther Clin Risk Manag; 2018; 14():2407-2413. PubMed ID: 30587997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Yoshihara F; Imazu M; Sakuma I; Hiroi Y; Hara H; Okazaki O; Ishiguro C; Izumi C; Noguchi T; Shiraiwa T; Nishioka N; Fujii K; Iwakura K; Tomonaga O; Kobayashi K; Takihata M; Yumoto K; Takase H; Himi T; Shimizu I; Murakami T; Wagatsuma K; Sato K; Hiramatsu T; Akabame S; Hata S; Asakura M; Kawabata T; Omae K; Ito S; Kitakaze M;
    EClinicalMedicine; 2023 Dec; 66():102334. PubMed ID: 38192595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-Coronary Artery Bypass Grafting Outcomes of Patients with/without Type-2 Diabetes Mellitus and Chronic Kidney Disease Treated with SGLT2 Inhibitor Dapagliflozin: A Single-Center Experience Analysis.
    Al Namat R; Duceac LD; Chelaru L; Dabija MG; Guțu C; Marcu C; Popa MV; Popa F; Bogdan Goroftei ER; Țarcă E
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial.
    Heerspink HJL; Oshima M; Zhang H; Li J; Agarwal R; Capuano G; Charytan DM; Craig J; de Zeeuw D; Di Tanna GL; Levin A; Neal B; Perkovic V; Wheeler DC; Yavin Y; Jardine MJ
    Am J Kidney Dis; 2022 Feb; 79(2):244-256.e1. PubMed ID: 34029680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.
    Papakitsou I; Vougiouklakis G; Elisaf MS; Filippatos TD
    Clin Pharmacol; 2019; 11():133-143. PubMed ID: 31572020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases.
    Berezin AE; Berezina TA
    J Int Med Res; 2024 Feb; 52(2):3000605241227659. PubMed ID: 38329077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Adaptive Renal Response for Volume Homeostasis During 2 Weeks of Dapagliflozin Treatment in People With Type 2 Diabetes and Preserved Renal Function on a Sodium-Controlled Diet.
    Scholtes RA; Muskiet MHA; van Baar MJB; Hesp AC; Greasley PJ; Hammarstedt A; Karlsson C; Hallow KM; Danser AHJ; Heerspink HJL; van Raalte DH
    Kidney Int Rep; 2022 May; 7(5):1084-1092. PubMed ID: 35570989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.